Twin Path Leads $1.75M Seed Round in AMPLY Discovery to Supercharge AI-Driven Drug Discovery
Backing AMPLY’s bold vision to tackle drug resistance and cancer using AI, next-gen sequencing, and synthetic biology.
We’re thrilled to welcome AMPLY Discovery into the Twin Path Ventures portfolio!
We’re proud to have led their $1.75M seed round, backing a standout Belfast team using AI, next-gen sequencing, and synthetic biology to tackle some of the world’s toughest diseases — from triple-negative breast cancer to antibiotic-resistant superbugs.
As our own Katie Lockwood puts it: “We’re impressed by Amply’s proprietary experimental dataset, their unique AI approach that incorporates human expertise, and their ability to validate discoveries in vitro and in vivo.”
What’s next for AMPLY?
Accelerating drug discovery pipelines
Expanding their biologics portfolio
Advancing precision therapies
Huge credit to the team: Ben Thomas, Dermot Tierney and the wider Amply crew
Read more:
https://lnkd.in/eVeHaJMa
https://lnkd.in/ev5HpYvZ